• 1. Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for demyelinating diseases
  Karla M. Ramos-Torres,Yu-Peng Zhou,Bo Yeun Yang,Nicolas J. Guehl,Moon Sung-Hyun,Sanjay Telu,Marc D. Normandin,Victor W. Pike,Pedro Brugarolas RSC Med. Chem. 2020 11 1161

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Methyl 3-iodopyridine-4-carboxylate (CAS No. 188677-49-8): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 3-iodopyridine-4-carboxylate (CAS No. 188677-49-8) is a highly versatile and significant compound in the realm of pharmaceutical chemistry. Its molecular structure, featuring both an iodine substituent and a carboxylate ester group, makes it an invaluable intermediate for the synthesis of various biologically active molecules. This compound has garnered considerable attention in recent years due to its role in the development of novel therapeutic agents, particularly in the fields of oncology and central nervous system (CNS) disorders.

The methyl 3-iodopyridine-4-carboxylate molecule is characterized by its pyridine core, which is a common scaffold in many pharmacologically relevant compounds. The presence of the iodine atom at the 3-position enhances its reactivity, making it a preferred building block for further functionalization via cross-coupling reactions such as Suzuki-Miyaura and Stille couplings. These reactions are pivotal in constructing complex heterocyclic frameworks, which are often essential for achieving the desired pharmacological properties.

In recent years, there has been a surge in research focused on developing new anticancer agents. Methyl 3-iodopyridine-4-carboxylate has emerged as a critical precursor in this endeavor. Its ability to undergo facile coupling with various aryl and vinyl halides allows for the rapid assembly of novel pyridine-based inhibitors targeting kinases and other enzymes involved in cancer progression. For instance, studies have demonstrated its utility in generating small-molecule inhibitors that disrupt the activity of tyrosine kinases, which are often overexpressed in tumors.

The carboxylate ester group in methyl 3-iodopyridine-4-carboxylate also provides a handle for further chemical modifications. It can be hydrolyzed to yield the corresponding pyridine carboxylic acid or converted into amides and esters, expanding its synthetic utility. This adaptability has made it a cornerstone in the synthesis of peptidomimetics and other protein-targeting ligands, which are increasingly being explored for their therapeutic potential.

Moreover, methyl 3-iodopyridine-4-carboxylate has found applications beyond oncology. In the field of central nervous system (CNS) drug discovery, its structural motifs have been incorporated into compounds targeting neurotransmitter receptors and ion channels. The pyridine ring is particularly well-suited for interacting with biological targets due to its ability to form hydrogen bonds and π-stacking interactions. Recent studies have highlighted its role in the development of novel antipsychotic and antidepressant agents, where it serves as a key structural component contributing to enhanced binding affinity and selectivity.

The synthesis of methyl 3-iodopyridine-4-carboxylate typically involves the iodination of pyridine derivatives followed by esterification. Advances in synthetic methodologies have enabled more efficient and scalable production processes, ensuring a steady supply for research and industrial applications. The compound's stability under various reaction conditions further adds to its appeal as a synthetic intermediate.

In conclusion, methyl 3-iodopyridine-4-carboxylate (CAS No. 188677-49-8) is a cornerstone compound in modern pharmaceutical synthesis. Its unique structural features and reactivity make it indispensable for constructing biologically active molecules across multiple therapeutic areas. As research continues to uncover new applications and synthetic strategies, this compound is poised to remain at the forefront of pharmaceutical innovation.

• 57842-10-1(3-Iodoisonicotinic acid)
• 1227269-05-7(Methyl 5-iodo-1h-indole-6-carboxylate)
• 10386-57-9(Ethyl 3-iodopyridine-4-carboxylate)
• 1033955-78-0(Methyl 4-iodopyridine-3-carboxylate)
• 1806412-28-1(Methyl 2-fluoro-5-iodoisonicotinate)
• 63473-00-7(ethyl 5-iodonicotinate)
• 88482-18-2(4-Pyridinecarboxylic acid, 5-iodo-2-methyl-)
• 88482-15-9(4-Pyridinecarboxylic acid, 5-iodo-2-methyl-, methyl ester)
• 873458-34-5(4-Pyridinecarboxylic acid, 3-iodo-, hydrochloride)
• 1033955-80-4(Methyl 5-iodopyridine-3-carboxylate)